Clinical Trial Update: Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial comparing AVE5026 with enoxaparin for prevention of venous thromboembolism in patients undergoing hip fracture surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• AVE5026
• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Sanofi | Conditions: Venous Thromboembolism | Phase 3 | Status: COMPLETED